|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Diaz-Garcia CV, Agudo-López A, Perez C,
López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A,
Martínez-Villanueva M, Iglesias L, García-Carbonero R, et al:
DICER1, DROSHA and miRNAs in patients with non-small cell lung
cancer: Implications for outcomes and histologic classification.
Carcinogenesis. 34:1031–1038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lau NC, Lim LP, Weinstein EG and Bartel
DP: An abundant class of tiny RNAs with probable regulatory roles
in Caenorhabditis elegans. Science. 294:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fiori ME, Barbini C, Haas TL, Marroncelli
N, Patrizii M, Biffoni M and De Maria R: Antitumor effect of
miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ.
21:774–782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bignell GR, Warren W, Seal S, Takahashi M,
Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, et al:
Identification of the familial cylindromatosis tumour-suppressor
gene. Nat Genet. 25:160–165. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kovalenko A, Chable-Bessia C, Cantarella
G, Israel A, Wallach D and Courtois G: The tumour suppressor CYLD
negatively regulates NF-kappaB signalling by deubiquitination.
Nature. 424:801–805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin X, Chen Q, Huang C and Xu X: CYLD
promotes TNF-α-Induced cell necrosis mediated by RIP-1 in human
lung cancer cells. Mediators Inflamm. 2016:15427862016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang YY, Wu ZY, Wang GC, Liu K, Niu XB, Gu
S and Meng JS: LINC00312 inhibits the migration and invasion of
bladder cancer cells by targeting miR-197-3p. Tumour Biol.
37:14553–14563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang YY, Wu ZY, Wang GC, Liu K, Niu XB, Gu
S and Meng JS: LINC00312 inhibits the migration and invasion of
bladder cancer cells by targeting miR-197-3p. Tumour Biol.
37:14553–14563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Xu Y, Cao X, Chen Y, Jiang J and
Wang K: Associations of Il-1 Family-Related polymorphisms with
gastric cancer risk and the role of Mir-197 In Il-1f5 Expression.
Medicine (Baltimore). 94:e19822015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim JH, Jono H, Komatsu K, Woo CH, Lee J,
Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, et al: CYLD negatively
regulates transforming growth factor-β-signalling via
deubiquitinating Akt. Nat Commun. 3:7712012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tauriello DV, Haegebarth A, Kuper I,
Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H
and Maurice MM: Loss of the tumor suppressor CYLD enhances
Wnt/beta-catenin signaling through K63-linked ubiquitination of
Dvl. Mol Cell. 37:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pannem RR, Dorn C, Ahlqvist K, Bosserhoff
AK, Hellerbrand C and Massoumi R: CYLD controls c-MYC expression
through the JNK-dependent signaling pathway in hepatocellular
carcinoma. Carcinogenesis. 35:461–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang WY, Lim JH and Li JD: Synergistic and
feedback signaling mechanisms in the regulation of inflammation in
respiratory infections. Cell Mol Immunol. 9:131–135. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gautheron J and Luedde T: A novel player
in inflammation and cancer: The deubiquitinase CYLD controls HCC
development. J Hepatol. 57:937–939. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Font-Burgada J, Seki E and Karin M: CYLD
and HCC: When being too sensitive to your dirty neighbors results
in self-destruction. Cancer Cell. 21:711–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Urbanik T, Köhler BC, Boger RJ, Wörns MA,
Heeger S, Otto G, Hövelmeyer N, Galle PR, Schuchmann M, Waisman A
and Schulze-Bergkamen H: Down-regulation of CYLD as a trigger for
NF-κB activation and a mechanism of apoptotic resistance in
hepatocellular carcinoma cells. Int J Oncol. 38:121–131.
2011.PubMed/NCBI
|
|
21
|
Hayashi M, Jono H, Shinriki S, Nakamura T,
Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M,
Murakami K, et al: Clinical significance of CYLD downregulation in
breast cancer. Breast Cancer Res Treat. 143:447–457. 2014.
View Article : Google Scholar : PubMed/NCBI
|
